Navigating Prior Authorization for Disability-Related Medical Services
Prior authorization is one of the most consequential administrative mechanisms in American healthcare — and for people with disabilities, it can determine whether prescribed treatment arrives on time or stalls for weeks behind paperwork. This page explains what prior authorization is, how the approval process operates, where it most frequently intersects with disability-related care, and how decisions get made (and challenged). The regulatory landscape is real and documented; so is the frustration.
Definition and scope
Prior authorization — sometimes called "preauthorization," "precertification," or "prior approval" — is a requirement by a health insurer that a provider obtain approval before delivering a specific service, medication, or piece of equipment. Without that approval, the insurer may refuse to pay, leaving the cost to the patient.
The scope of prior authorization in disability care is broad. The Centers for Medicare & Medicaid Services (CMS) oversees prior authorization rules across Medicare Advantage, Medicaid managed care, and the federal marketplace plans established under the Affordable Care Act. For Medicaid specifically — the program that covers a disproportionately large share of people with disabilities, as explored in Medicaid and disability coverage — states operate their own managed care contracts, meaning prior authorization thresholds vary by state.
The No Surprises Act and the Consolidated Appropriations Act of 2021 introduced federal transparency requirements for prior authorization, and CMS finalized a rule in January 2024 requiring most federally regulated payers to respond to prior authorization requests within 72 hours for urgent cases and 7 calendar days for standard requests (CMS Prior Authorization Rule, CMS-0057-F).
How it works
The prior authorization process follows a structured sequence, though the friction points are well-documented:
- The treating provider identifies a service — a durable medical device, a specialist referral, a rehabilitation therapy course, a high-cost medication — that falls on the insurer's list of covered services requiring pre-approval.
- The provider submits a request to the insurer, typically including clinical notes, diagnostic codes, and a letter of medical necessity. For disability-related services, a functional assessment or evaluation by a physiatrist or licensed specialist often anchors this documentation.
- The insurer's utilization review team evaluates the request against internal clinical criteria. Insurers are required under federal law to base these criteria on evidence-based standards — the National Committee for Quality Assurance (NCQA) sets accreditation standards for utilization management that many insurers follow.
- A decision is issued: approval, denial, or a request for additional information (peer-to-peer review). If denied, the insurer must provide a written explanation citing the clinical basis.
- Appeals follow denial. Internal appeals must be exhausted before external independent review, which is available in all 50 states under the ACA's external review provisions.
The distinction between a concurrent review (for ongoing services) and a prospective review (before treatment begins) matters considerably. Concurrent reviews can interrupt active rehabilitation mid-course — a scenario especially disruptive for people recovering from spinal cord injury or traumatic brain injury, where continuity of care is clinically significant.
Common scenarios
Prior authorization surfaces most frequently in disability-related care across four categories:
Durable medical equipment (DME): Power wheelchairs, custom orthotics, and augmentative communication devices consistently trigger prior authorization requirements. CMS requires suppliers to obtain a written order and, for complex rehabilitation technology, a face-to-face evaluation documented by a physician or qualified therapist before submitting for coverage.
Behavioral and mental health services: Applied behavior analysis (ABA) for autism, intensive outpatient psychiatric programs, and long-term psychotherapy sessions require prior authorization under most commercial and Medicaid managed care plans. The Mental Health Parity and Addiction Equity Act (MHPAEA) prohibits insurers from applying more restrictive prior authorization requirements to mental health benefits than to comparable medical benefits — a protection directly relevant to psychiatric and mental health disabilities.
Specialty pharmaceuticals: Biologic medications for conditions like multiple sclerosis or certain immunological disorders that underlie disability often carry step-therapy requirements — insurers may require a patient to fail on a cheaper drug before authorizing the prescribed medication.
Rehabilitation services: Physical therapy, occupational therapy, and speech-language pathology visits are frequently subject to visit limits that require authorization at specified thresholds. This intersects heavily with rehabilitation medicine and disability and assistive technology for disability, where equipment training and therapy are often intertwined.
Decision boundaries
Prior authorization decisions are not arbitrary — they operate within specific regulatory guardrails, even if those guardrails feel distant when a claim is denied.
Insurers must apply clinical review criteria that are based on sound clinical evidence, as required by the Utilization Review Accreditation Commission (URAC) standards and the NCQA guidelines. A denial cannot rest on cost alone. Federal Medicaid regulations at 42 CFR Part 438 set requirements for managed care organizations around authorization timeliness and the scope of reviewable services.
The line between a medical necessity denial and a coverage exclusion denial carries practical weight. Medical necessity denials can be appealed by demonstrating clinical justification — peer-reviewed literature, specialist letters, functional assessments. Coverage exclusion denials (where the service simply isn't a covered benefit) require a different path, often involving the disability benefits application process or a review of alternative coverage through programs like state vocational rehabilitation programs.
Expedited review — the 72-hour pathway under the 2024 CMS rule — is available when the standard timeline could seriously jeopardize a patient's life, health, or ability to regain maximum function. Clinicians must explicitly request expedited review and document the clinical urgency. This is not a minor procedural detail: for someone whose condition is time-sensitive, knowing to ask for expedited review can be the difference between receiving a wheelchair in days rather than months.
The regulatory context for disability and the protections under Section 504 of the Rehabilitation Act also intersect here — a denial that effectively excludes a person with a disability from medically necessary care may have civil rights dimensions beyond standard insurance appeals, a dimension worth raising with a patient advocate or disability rights organization.